[Cannabinoid mouth spray brought help to a severely spastic young man]

Duodecim. 2014;130(14):1452-4.
[Article in Finnish]


Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland. Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Administration, Oral
  • Adult
  • Cannabinoids / administration & dosage*
  • Cerebral Palsy / drug therapy*
  • Cerebral Palsy / physiopathology
  • Finland
  • Humans
  • Male
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / physiopathology
  • Quality of Life


  • Cannabinoids